San Antonio—The combination of PI3K inhibitor buparlisib and endocrine therapy with fulvestrant improved progression-free survival (PFS) in ...
News
- SABCS 2016: Buparlisib Improves PFS in BELLE-3 Study, But Toxicity Is Concerning
- What the 114th Congress did and didn't do
A sweeping biomedical bill that would help drug and medical device companies win swifter government approval of their products, boost disease ...
- Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in ...
SAN ANTONIO--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today presented data from an ongoing ...
- Calithera Biosciences to Host Conference Call and Webcast to Review Data Presented at the San ...
... clinical data presentations at the San Antonio Breast Cancer Symposium, ... Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company ...
- KU professor's research proves some science textbooks wrong
Haufler's research is reported in the November issue of the journal Bioscience, in an article he co-authored with a group he said one reviewer ...